Retatrutide, also known by its research name LY-3437943, is an investigational once-weekly injectable drug developed by Eli Lilly
For thyroid patients, this test reveals genetic predispositions toward weight resistance and metabolic sluggishness that semaglutide is uniquely effective at addressing, helping your PlexusDx provider optimize your personalized protocol from day one
Graf MV, Kastin AJ
Electrolytes (Sodium, Potassium, Magnesium) Prevents dehydration and reduces nausea, headaches, and muscle cramps
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes - SURPASS-2
Phase I studies from the late 1980s using IGF-1 to treat Larons Syndrome (GH insensitivity) revealed effective increase in linear growth reaching adult heights using doses ranging from 80 to 240 g/kg/day [264268]